RENOVARO INC. - COMMON STOCK

Enochian BioSciences Forges Ahead With Focused Approach, Promising Future

24 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K

21 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform

17 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

25 Jul 2022 09:15:16 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data

01 Jul 2022 16:00:00 By Nasdaq GlobeNewswire

Scientific Leaders Agree on Promise of Enochian BioSciences

31 May 2022 07:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company

25 May 2022 15:20:30 By Nasdaq GlobeNewswire

Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience

20 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer

07 Apr 2022 05:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit

05 Apr 2022 05:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans

15 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors

03 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month

18 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

15 Oct 2021 17:00:00 By Nasdaq GlobeNewswire

Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

12 Oct 2021 17:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection

27 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference

13 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants

30 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board

23 Aug 2021 09:18:10 By Nasdaq GlobeNewswire

Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer

20 Jul 2021 06:00:01 By Nasdaq GlobeNewswire